Relationship between functional and non-functional parameters, and quality of life and CRP in patients with chronic obstructive pulmonary disease;Kronik obstrüktif akciger hastalarinda fonksiyonelve non-fonksiyonel parametreler ile yasam kalitesive C-reaktif protein (CRP) arasindaki iliski

Gulhane Medical Journal

Volumn 54, Issue 2, 2012, Pages 93-103

  Sengören, Özlem ^a   Anar, Ceyda ^a   Usta, Levent ^b   Özacar, Rifat ^a   Halilçolar, Hüseyin ^a   Biçmen, Can ^a  

^a Izmir Dr Suat Seren Gögüs Hastaliklari ve Gögüs Cerrahisi   (Turkey)

^b Izmir Tepecik Egitim Arastirma Hastanesi Gögüs Hastaliklari   (Turkey)

Author keywords

Chronic obstructive pulmonary disease; Quality of life; Systemic inflammation

Indexed keywords

EID: 84865177748     PISSN: 13020471     EISSN: None     Source Type: Journal    
DOI: 10.5455/gulhane.21067     Document Type: Article

References (38)

1. Pavwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620.
2. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available at: www.goldcopd.com. (Accessed Nov 2006).
3. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1444.
4. Anderseon GP. COPD, asthma and C reactive protein. Eur Respir J 2006; 27: 874-876.
5. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005; 99: 670-682.
6. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004; 59: 574-580.
7. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
8. Debigaré R, Côté CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001; 164: 1712-1717.
9. Mahler DA. How should health related quality of life be assessed in patients with COPD? Chest 2000; 117: 54-57.
10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
11. Devon WJ. Medical Research Council on research into chronic bronchitis. Instructions for use of the questionnaire on respiratory symptoms. 1966.
12. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758-762.
13. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
14. Sin DD, Lacy P, York E, Mann SF. Effects of fluticasone on systematic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765.
15. Wu SJ, Chen P, Jiang XN, Liu ZJ. C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2005; 30: 444-446.
16. De Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.
17. Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J; EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010; 11: 63.
18. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1008-1011.
19. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, et al. Chronic airflow obstruction and markers of systemic inflammation: Results from the BOLD study in Iceland. Respir Med 2009; 103: 1548-1555.
20. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD. The Framingham Heart Study. Chest 2008; 133: 19-25.
21. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007; 62: 515-520.
22. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
23. Savci S, Inal D, Arikan H. Orta ve siddetli obstrüksiyonu olan KOAH'li hastalarda alti dakikalik yürüme testini belirleyen faktörler. Solunum Hastaliklari 2000; 11: 231-236.
24. Soyyigit S, Erk M, Güler N, Kilinç G. Kronik obstruktif akciger hastaliginda yasam kalitesinin belirlenmesinde SF-36 saglik taramasinin yeri. Tüberküloz ve Toraks Dergisi 2006; 54: 259-266.
25. Sant'Anna CA, Stelmach R, Zanetti Feltrin MI, Filho WJ, Chiba T, Cukier A. Evaluation of health-related quality of life in low-income patients with COPD receiving long term oxygen therapy. Chest 2003; 123: 136-141.
26. Stavem K, Boe J, Erikssen J. Health status, dyspnea, lung function and exercise capacity in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 1999; 3: 920-926.
27. Boueri FM, Bucher-Bartelson BL, Glenn KA, Make BJ. Quality of life measured with a generic instrument (SF-36) improves following pulmonary rehabilitation in patients with COPD. Chest 2001; 119: 77-84.
28. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1072-1079.
29. Pereira ED, Pinto R, Alcantara M, Medeiros M, Mota RM. Influence of respiratory function parameters on the quality of life of COPD patients. J Bras Pneumol 2009; 35: 730-736.
30. Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 103: 395-401.
31. Mahler DA, Tomlinson D, Olmstead EM, et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995; 151: 61-65.
32. Mahler DA, Mackowiak JI. Evaluation of the shortform 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 1995; 107: 1585-1589.
33. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
34. Katsura H, Yamada K, Kida K. Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005; 99: 624-630.
35. Siafakas NM, Schiza S, Xirouhaki N, et al. Is dyspnoea the main determinant of quality of life in the failing lung?: a review. Eur Respir Rev 1997; 7: 53-56.
36. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
37. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Comparison of 61 discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Med 1998; 157 (3 Pt 1): 785-790.
38. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea disaese severity in indicating the health related quality of life of patients with COPD. Chest 1999; 116: 1632-1637.